Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Patrick Y. Wen, Michael Weller, Eudocia Q. Lee, Mehdi Touat, Mustafa Khasraw, Rifaquat Rahman, Michael Platten, Michael Lim, Frank Winkler, Craig Horbinski, Roel G.W. Verhaak, Raymond Y. Huang, Manmeet S. Ahluwalia, Nathalie L. Albert, J. C. Tonn, David Schiff, Jill S. Barnholtz‐Sloan, Quinn T. Ostrom, Kenneth Aldape, Tracy T. Batchelor, Ranjit S. Bindra, E. Antonio Chiocca, Timothy F. Cloughesy, John DeGroot, Pim J. French, Evanthia Galanis, Norbert Galldiks, Mark R. Gilbert, Monika E. Hegi, Andrew B. Lassman, Émilie Le Rhun, Minesh P. Mehta, Ingo K. Mellinghoff, Giuseppe Minniti, Patrick Roth, Marc Sanson, Martin Taphoorn, von Deimling, Tobias Weiss, Wolfgang Wick, Gelareh Zadeh, David A. Reardon, Susan M. Chang, Susan Short, Martin J. van den Bent, Matthias Preusser
Abstract
Glioblastoma is the most common type of malignant primary brain tumor and a major cause of morbidity and mortality. In 2021, the World Health Organization updated the classification of Central Nervous System (CNS) tumors to restrict glioblastomas to isocitrate dehydrogenase-wildtype (IDHwt) tumors, improving understanding of the prognosis and optimal therapy for these tumors. This revision also enables more homogeneous populations of patients to be enrolled in clinical trials, facilitating the evaluation of novel therapies. In this updated consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of patients with glioblastoma is discussed. In addition, novel therapies such as immunotherapies, viral therapies, targeted molecular therapies, theranostics, and antibody-drug conjugates will be reviewed, as well as the current challenges and future directions for research.